Star condemned Trump for refusing to concede
China’s latest trip to the moon is another milestone in the Asian powerhouse’s slow but steady ascent to the stars. China became the third country to put a person into orbit a generation ago and the first to land on the far side of the moon in 2019. Future ambitions include a permanent space station and putting people back on the moon more than 50 years after the U.S. did.
‘Alex believed in the importance of Jeopardy and always said that he wanted the show to go on after him,’ executive producer Mike Richards said
The Chinese Uber for trucks Manbang announced Tuesday that it has raised $1.7 billion in its latest funding round, two years after it hauled in $1.9 billion from investors including SoftBank Group and Alphabet Inc's venture capital fund CapitalG. The news came fresh off a Wall Street Journal report two weeks ago that Manbang was seeking $1 billion ahead of an initial public offering next year. The company declined to comment on the matter, though its CEO Zhang Hui said in May 2019 that the firm was "not in a rush" to go public.
‘Scotland will not be the last country to make period poverty history — but it now has a chance to be the first’
Save on comforter and comforter set deals at the Black Friday sale, featuring down, quilted, and reversible comforter, duvet, and duvet set deals
China on Tuesday reported two new coronavirus cases in the cities of Shanghai and Tianjin as it seeks to prevent small outbreaks from becoming larger ones. The National Health Commission said that there were two new locally spread cases in the previous 24-hour period, one in each city. It also reported 20 cases among people who had arrived from overseas.
The Puerto Rican star canceled his performance at last night’s AMAs but did appear remotely to present the award for favorite Latin female artist
Police have launched an investigation and notified Interpol.
With less than a week to go until the big day, the giant retailer has begun its countdown with more impressive offers
French President Emmanuel Macron is expected to announce a reworking of the country’s Covid-19 lockdown rules in a televised speech Tuesday night following a drop in nationwide infections. France is expected to start easing Covid-19 lockdown rules in coming weeks, carrying out the process in three stages so as to avoid a new flareup in the pandemic, according to senior officials.In his speech Tuesday, Macron is expected to announce an adjustment of restrictions that have been in place since October 30."Emmanuel Macron will give prospects over several weeks, especially on how we adjust our strategy. What is at stake is adapting lockdown rules as the health situation improves while avoiding a new flare-up in the epidemic," government spokesman Gabriel Attal told the French weekly, Le Journal Du Dimanche."There will be three steps to (lockdown) easing in view of the health situation and of risks tied to some businesses: a first step around December 1, then before the year-end holidays, and then from January 2021," Attal added.Macron had said France's second national lockdown would last at least four weeks. Curbs include the closure of non-essential stores, restaurants and bars.But with recent data showing France on track to rein in a surge in coronavirus infections, the government is under pressure from shops and businesses to ease restrictions in time for the Christmas shopping season, when many retailers make the bulk of their annual turnover."We had committed to allow them (shopkeepers) to reopen around December 1 if the health situation improved, which seems to be the case," Attal said.Bars and restaurants, however, "will continue to experience restrictions," he added.Light at end of 'long, dark tunnel'Macron’s address comes a day after drug firm AstraZeneca and Oxford University announced a vaccine in development had proved “very effective” in trials involving 23,000 people.The announcement came after other trials of drugs developed by Pfizer/BioNTech and Moderna announced effectiveness above 90 percent.The developments have provided a boost to virus-weary citizens across the globe as the holiday season approaches.While World Health Organization Director-General Tedros Adhanom Ghebreyesus hailed the latest batch of results as light at the end of the "long dark tunnel", he cautioned the world had to ensure drugs were distributed fairly."Every government rightly wants to do everything it can to protect its people," Tedros said. "But there is now a real risk that the poorest and most vulnerable will be trampled in the stampede for vaccines."On Thursday, French Health Minister Olivier Veran said the country will win its battle against the coronavirus but it is a struggle that will take time, warning the lockdown was not yet over.(FRANCE 24 with AP, AFP and REUTERS)
‘If you’re telling a story about a community and they’re not welcoming to you, then f*** off,’ said star
Once the preserve of gamers, virtual reality (VR) has been seized on by the financial sector as a way of enlivening home working for lonely traders or isolated executives and replicating real-world sales, networking or training events. "Working from home has massively accelerated the interest in virtual/online spaces," said Stuart Warner, head of technology at Fidelity International which manages $3.3 trillion in assets. Having internally explored VR and augmented reality (AR) technology, which unlike VR is not fully immersive and involves computer-generated elements being visible through a smartphone screen for example, Fidelity now aims to trial VR with its sales teams' interactions with clients.
DGAP-News: HYPOPORT SE / Key word(s): Market launch 24.11.2020 / 08:20 The issuer is solely responsible for the content of this announcement. Thanks to Europace and Smart InsurTech, Sparda BW enables payment protection insurance linked to mortgage finance to be taken out digitally Bancassurance: Europace credit platform and SMART INSUR insurance platform seamlessly integrated with each other for the first time Berlin, 24 November 2020. For the first time, Europace - the largest German transaction platform for mortgage finance, building finance products, and personal loans - and the web-based SMART INSUR insurance platform can communicate with each other directly. In cooperation with Sparda-Bank Baden-Württemberg eG (Sparda BW), a standard connection was developed that enables payment protection insurance to be taken out digitally in conjunction with a mortgage finance application. "We want to digitalise our processes and reduce manual tasks that take up a lot of time so that our advisors can focus more on looking after clients while administrative staff can concentrate on value-adding tasks," says Michael Lichtner, Back Office Head of Department at Sparda BW, explaining the reasons for the joint project. "This not only improves our efficiency but also enables us to avoid errors that might potentially occur in manual processes." Thanks to the cooperation between Smart InsurTech AG and Europace AG, both of which are wholly owned subsidiaries of Hypoport SE, an advisor who applies for mortgage finance for their client using Europace's Baufi Smart frontend receives an offer for payment protection insurance and thus benefits from the Smart Compare comparison tool. Smart Compare connects the mortgage finance advisors to the product supplier Credit Life, enabling a quote to be requested almost in real time. Stefan Münter, Co-CEO of Europace, adds: "We are delighted that Sparda BW, a long-standing customer of the credit platform, has teamed up with us for this project. The collaboration between the two Hypoport companies allows us to be a one-stop shop for Sparda BW, providing the best possible process for advisors and end clients. It was important for us to create a standard interface to the SMART INSUR insurance platform as it means we can offer a link to payment protection insurance as part of the mortgage finance application process for all prospective customers in future." Besides the synergies, another benefit of the interface between the credit and insurance platforms is the high level of data security because both systems are part of the Hypoport Group and thus no external service providers are involved. Care was taken to maintain a separation between the two companies, with each one working in their own domain and only with access to the data that it actually needs. "By combining the expertise of Europace and Smart InsurTech, we can make inroads into new markets," reports Marcus Rex, member of the Management Board of Smart InsurTech AG. "It provides the blueprint for the integration of further payment protection insurance products. Any such product can be integrated through the interface, so it opens up huge market potential." About Hypoport SE Hypoport SE is headquartered in Lübeck (Germany) and is the parent company of the Hypoport Group. The Group is a network of technology companies for the credit, real-estate and insurance industries with a workforce of more than 2,000 employees. It is grouped into four segments: Credit Platform, Private Clients, Real Estate Platform and Insurance Platform. The Credit Platform segment operates Europace, which is an online B2B financial marketplace and the largest German platform offering mortgages, building finance products and personal loans. A fully integrated system links more than 750 partners - banks, insurers and financial product distributors. Several thousand loan brokerage advisors execute approx. 35,000 transactions per month on Europace, generating a volume of more than €7 billion. Besides Europace, the FINMAS and GENOPACE sub-marketplaces and the B2B distribution companies Qualitypool and Starpool support the growth of the credit platform. The Private Clients segment, made up of the web-based, non-captive financial product distributor Dr. Klein Privatkunden and the consumer comparison portal Vergleich.de, brings together all business models aimed at directly advising consumers on mortgages, insurance or pension products. All real estate-related activities of the Hypoport Group, with the exception of mortgage finance, are grouped together in the Real Estate Platform segment (previously Institutional Clients) with the aim of digitalising the sale, valuation, financing and management of properties. The Insurance Platform segment operates SMART INSUR, a web-based B2B platform for advice, comparison of tariffs and the administration of insurance policies. The segment also incorporates the insurance unit of Qualitypool, a B2B distribution company. The shares of Hypoport SE are listed in the Prime Standard segment of the Frankfurt Stock Exchange (Deutsche Börse) and have been included in the SDAX since 2015. Contact Jan H. Pahl Investor Relations Manager Phone: +49 (0)30 / 42086 - 1942 Mobile: +49 (0)176 / 965 125 19 Email: firstname.lastname@example.org Hypoport SE Heidestraße 8 10557 Berlin www.hypoport.com Key data on Hypoport's shares ISIN DE 0005493365 WKN 549336 Stock exchanges symbol HYQ 24.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: HYPOPORT SE Heidestraße 8 10557 Berlin Germany Phone: +4930420861942 Fax: +49/30 42086-1999 E-mail: email@example.com Internet: www.hypoport.de ISIN: DE0005493365 WKN: 549336 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1150129 End of News DGAP News Service
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Diabetes Drug Delivery Devices Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes drug delivery devices. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall diabetes drug delivery devices market with a detailed market segmentation on the [A] type of device (pen-injectors, insulin pumps, conventional syringes and others), [B] route of administration (subcutaneous, intravenous and others), [C] diabetes type (type 1 diabetes and type 2 diabetes), [D] device usability (disposable and reusable) and [E] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.Amongst other elements, the report includes: An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector/autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin). In addition, the report present the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size and location of headquarters.A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage).An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering technology integration agreements, product development agreements, distribution agreements, acquisitions, product commercialization agreements, supply agreements, licensing agreements, product development and commercialization agreements and other relevant types of deals.Elaborate profiles of the prominent players developing diabetes drug delivery devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.A review of recent initiatives undertaken by big pharma players engaged in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), based on their initiatives related to diabetes drug delivery devices. Key Topics Covered: 1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Chapter Overview3.2. An Overview of Diabetes3.2.1. Classification of Diabetes126.96.36.199. Type 1 Diabetes188.8.131.52. Type 2 Diabetes3.3. Route of Administration for Diabetes Drugs3.3.1. Buccal Route3.3.2. Inhalation Route3.3.3. Intradermal Route3.3.4. Intramuscular Route3.3.5. Intranasal Route3.3.6. Oral Route3.3.7. Subcutaneous Route3.4. Key Challenges Associated with Delivery of Diabetes Drugs3.5. Diabetes Drug Delivery Devices3.5.1. Implants3.5.2. Inhalation Devices3.5.3. Insulin Ports3.5.4. Insulin Pumps3.5.5. Jet Injectors3.5.6. Microneedle Patches3.5.7. Nasal Delivery Devices3.5.8. Pen-Injectors/Autoinjectors3.6. Concluding Remarks4. CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. Diabetes Drug Delivery Devices: Overall Market Landscape4.2.1. Analysis by Type of Device4.2.2. Analysis by Stage of Development4.2.3. Analysis by Route of Administration4.2.4. Analysis by Mode of Drug Delivery4.2.5. Analysis by Needle Attributes4.2.6. Analysis by Type of Drug Delivery System4.2.7. Analysis by Drug Administration Speed4.2.8. Analysis by Device Usability4.2.9. Analysis by Diabetes Type4.2.10. Analysis by Type of Drug4.3. Diabetes Drug Delivery Devices: List of Developers4.3.1. Analysis by Type of Developer4.3.2. Analysis by Year of Establishment4.3.3. Analysis by Company Size4.3.4. Analysis by Location of Headquarters4.3.5. Leading Manufacturers: Analysis by Number of Products5. PRODUCT COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Assumptions and Methodology5.2.1. Product Competitive Analysis: Diabetes Drug Delivery Devices6. PARTNERSHIPS AND COLLABORATIONS6.1. Chapter Overview6.2. Partnership Models6.3. Diabetes Drug Delivery Devices: List of Partnerships and Collaborations6.3.1. Analysis by Year of Partnership6.3.2. Analysis by Type of Partnership6.3.3. Analysis by Year and Type of Partnership6.3.4. Analysis by Type of Device6.3.5. Most Active Players: Analysis by Number of Partnerships6.3.6. Geographical Analysis184.108.40.206. Region-wise Distribution220.127.116.11. Country-wise Distribution7. COMPANY PROFILES7.1. Chapter Overview7.2. Bigfoot Biomedical7.2.1. Company Overview7.2.2. Diabetes Drug Delivery Device Portfolio7.2.3. Recent Developments and Future Outlook7.3. Debiotech7.4. Haselmeier7.5. Medtronic7.6. Novo Nordisk7.7. Roche7.8. SOOIL7.9. Ypsomed8. DIABETES DRUG DELIVERY DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS8.1. Chapter Overview8.2. Scope and Methodology8.3. Initiatives of Big Pharma Players8.3.1. Analysis by Diversity in Device Portfolio8.3.2. Analysis by Phase of Development8.3.3. Analysis by Diabetes Type8.3.4. Analysis by Type of Drug8.3.5. Analysis by Number of Partnerships8.4. Benchmark Analysis of Big Pharma Players9. MARKET SIZING AND OPPORTUNITY ANALYSIS9.1. Chapter Overview9.2. Forecast Methodology and Assumptions9.3. Overall Diabetes Drug Delivery Devices Market, 2020-20309.3.1. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device9.3.2. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration9.3.3. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type9.3.4. Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability9.3.5. Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution18.104.22.168. Diabetes Drug Delivery Devices Market in North America, 2020-20309.3.5.2. Diabetes Drug Delivery Devices Market in Europe, 2020-20309.3.5.3. Diabetes Drug Delivery Devices Market in Asia Pacific, 2020-20309.3.5.4. Diabetes Drug Delivery Devices Market in Rest of the World, 2020-203010. CONCLUDING REMARKS10.1. Chapter Overview10.2. Key Takeaways11. EXECUTIVE INSIGHTS12. APPENDIX 1: TABULATED DATA For more information about this report visit https://www.researchandmarkets.com/r/ia6njg Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Man at centre of South Australia lockdown 'extremely remorseful and deeply sorry'Solicitor acting for the 36-year-old man released a statement on Tuesday saying some information circulating was not ‘accurate’
EXCLUSIVE: Pete Davidson is taking on an iconic film character, James Stewart’s George Bailey. The Saturday Night Live actor and Maude Apatow (Euphoria), who recently starred together in The King of Staten Island, are reuniting for Ed Asner’s one-night-only live virtual celebrity table read of the 1946 holiday classic It’s A Wonderful Life, in which […]
An investigation by Which? found 85% of products it tracked could be found cheaper or the same price in the six months before.
Taiwan President Tsai Ing-wen kicks off construction of the island's first indigenous submarine at a Kaohsiung shipyard, the latest move by the out-gunned democratic island to bolster its defence capabilities against increasingly bellicose threats from Beijing.
As Ethiopia’s army declares daily victories, its people are being plunged into violence. Abiy Ahmed’s war against Tigrayan rebels endangers a fragile union whose collapse would destabilise the Horn of Africa